Sana Biotechnology, Inc. (SANA) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended September 30, 2024. Sana Biotechnology, Inc. is a clinical-stage biotechnology company developing engineered cell therapies for type 1 diabetes, B-cell mediated autoimmune diseases, and oncology. The company operates as an emerging growth company and has incurred significant losses since inception, with no products currently approved for commercial sale.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(59.9) million | $0.98 million (Income) | $(217.7) million | $(195.1) million |
| Operating Expenses | $61.8 million | $2.2 million | $221.9 million | $202.5 million |
| Cash & Equivalents | $127.0 million | $133.5 million | $127.0 million | $133.5 million |
| Marketable Securities | $72.0 million | $71.7 million | $72.0 million | $71.7 million |
| Total Liquidity | $199.0 million | $205.2 million | $199.0 million | $205.2 million |
| Accumulated Deficit | $(1.56) billion | $(1.25) billion | $(1.56) billion | $(1.25) billion |
Note: All figures in millions unless otherwise noted. The company reported a net loss for Q3 2024 compared to a net income in Q3 2023, primarily driven by changes in the fair value of contingent consideration and success payment liabilities.
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses increased significantly in Q3 2024 ($61.8M) compared to Q3 2023 ($2.2M). This increase is largely due to a reversal of non-cash gains recorded in the prior year related to the revaluation of success payment liabilities and contingent consideration. In Q3 2023, the company recorded a massive non-cash gain of $82.6M in this category, whereas Q3 2024 recorded a non-cash gain of only $5.5M.
- Research & Development (R&D): Cash-based R&D expenses decreased to $53.2M in Q3 2024 from $65.6M in Q3 2023, reflecting a strategic repositioning and reduced headcount initiated in late 2023.
- Financing Activity: In February 2024, the company completed an underwritten public offering raising approximately $180.0 million in net proceeds. Additionally, the company utilized its At-The-Market (ATM) facility, raising $28.6 million in net proceeds year-to-date.
- Capital Expenditures: Purchases of property and equipment increased to $33.0 million for the nine months ended September 30, 2024, compared to $6.0 million in the same period in 2023, driven by the build-out of the Bothell, Washington manufacturing facility.
Guidance, Outlook, and Risks
- Strategic Repositioning (Subsequent Event): On November 4, 2024, the company announced a strategic repositioning to prioritize type 1 diabetes, B-cell mediated autoimmune diseases, refractory B-cell malignancies, and the fusogen platform. Consequently, development of SC291 (oncology) and SC379 (glial progenitor cell program) will be suspended to seek partnerships.
- Workforce Reduction: The strategic repositioning resulted in a workforce reduction of approximately 45%. The company expects to incur approximately $6.4 million in cash-based severance and related costs, with the reduction expected to be substantially complete in Q1 2025.
- Liquidity Outlook: As of September 30, 2024, the company held $199.0 million in cash, cash equivalents, and marketable securities. Management believes this is sufficient to fund operations for at least 12 months from the filing date.
- Contingent Liabilities: The company has significant contingent consideration and success payment obligations from the acquisition of Cobalt Biomedicine and a license agreement with Harvard College. These liabilities are marked to market quarterly, causing significant volatility in reported net income/loss. As of September 30, 2024, the estimated fair value of these liabilities was approximately $127.0 million ($111.9M contingent consideration + $15.1M success payments).
- Risks: Key risks include the need for additional capital, the uncertainty of clinical trial outcomes, regulatory hurdles for novel cell therapies, and the potential for significant fluctuations in financial results due to fair value adjustments of contingent liabilities.
Investor Verification Checklist
- Cash Runway: Verify the impact of the 45% workforce reduction and the $6.4M severance cost on the projected 12-month cash runway.
- Non-Cash Volatility: Review the specific assumptions used to value the Cobalt contingent consideration and success payment liabilities, as these drive significant swings in net income/loss unrelated to operational cash flow.
- Manufacturing Progress: Assess the status and cost of the Bothell manufacturing facility build-out, which drove a 450% increase in capital expenditures year-over-year.
- Program Suspension: Confirm the timeline for winding down the ARDENT trial (SC291) and the strategy for seeking partnerships for the suspended programs.
- Financing Needs: Evaluate the remaining capacity under the $150M ATM facility and the likelihood of future dilutive equity raises given the lack of product revenue.